Accéder au contenu
Merck

Type IV Collagen in Human Colorectal Liver Metastases-Cellular Origin and a Circulating Biomarker.

Cancers (2022-07-28)
Moa Lindgren, Gunilla Rask, Josefin Jonsson, Anette Berglund, Christina Lundin, Pär Jonsson, Ingrid Ljuslinder, Hanna Nyström
RÉSUMÉ

Circulating type IV collagen (cCOL IV) is a potential biomarker for patients with colorectal liver metastases (CLM) who present with elevated levels of COL IV in both CLM tissue and circulation. This study aimed to establish the cellular origin of elevated levels of COL IV and analyze circulating COL IV in CLM patients. The cellular source was established through in situ hybridization, immunohistochemical staining, and morphological evaluation. Cellular expression in vitro was assessed by immunofluorescence. Tissue expression of COL IV-degrading matrix metalloproteinases (MMPs)-2, -7, -9, and -13 was studied with immunohistochemical staining. Plasma levels of COL IV in CLM patients and healthy controls were analyzed with ELISA. This study shows that cancer-associated fibroblasts (CAFs) express COL IV in the stroma of CLM and that COL IV is expressed in vitro by fibroblasts but not by tumor cells. MMP-2, -7, -9, and -13 are expressed in CLM tissue, mainly by hepatocytes and immune cells, and circulating COL IV is significantly elevated in CLM patients compared with healthy controls. Our study shows that stromal cells, not tumor cells, produce COL IV in CLM, and that circulating COL IV is elevated in patients with CLM.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-Collagen Type IV Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Anti-MMP-2 Antibody, pro and active form, clone A-Gel VC2, clone A-Gel VC2, Chemicon®, from mouse